Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04845178 · ClinicalTrials.gov registry record · Phase 2
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
A Phase 2 study, sponsored by AEON Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 797
- Enrollment target
NCT04845178 is a Phase 2 study that has completed, run by AEON Biopharma. The registered enrollment target is 797 participants.
The verdict
NCT04845178, a Phase 2 study, has completed, sponsored by AEON Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 797 participants
- Enrollment target
Study Summary
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the Company's novel injection paradigm.
Interventions
- DRUG Placebo
- DRUG ABP-450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 797 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04845178
The ClinicalTrials.gov registry entry for NCT04845178 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 797 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEON Biopharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04845178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04845178 about?
NCT04845178 is a clinical study titled "Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults". This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenl...
What is the current status of trial NCT04845178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 797 participants. The study started on 2021-03-01. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT04845178?
The interventions under investigation include: Placebo (DRUG), ABP-450 (DRUG).
Who is sponsoring clinical trial NCT04845178?
This trial is sponsored by AEON Biopharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.